The Role of EGFR Tyrosine Kinase Inhibitors in the First-Line Treatment of Advanced Non Small Cell Lung Cancer Patients Harboring EGFR Mutation
Keywords: Acquired resistance; advanced NSCLC; epidermal growth factor mutation; erlotinib; first-line treatment; fluorescence in situ hybridization; gefitinib; immunohistochemistry; mutation detection; polymerase chain reaction; primary resistance; targeted therapy
Document Type: Research Article
Publication date: 2012-07-01
- Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.